Carcereny E, Felip E, Reck M, et al. Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC. 18th World Conference on Lung Cancer (WCLC) 2017, abstract OA 17.02.
Datopotamab deruxtecan bij gevorderde HR+/HER2- en tripelnegatieve borstkanker
jun 2024 | Borstkanker